Search results
Dr. Walensky is a pediatric hematology/oncology physician and researcher at Dana-Farber and Harvard Medical School. He develops novel peptide drugs for cancer and studies oncogenic pathways.
Loren David Walensky is an American physician-scientist and pediatric oncologist at the Dana–Farber Cancer Institute since 2003 and a professor of pediatrics at the Dana–Farber/Harvard Cancer Center. He researches peptides and oncogenic pathways. In 2013, Walensky became director of the joint MD/PhD program at Harvard Medical School.
- 3
- .mw-parser-output .marriage-line-margin2px{line-height:0;margin-bottom:-2px}.mw-parser-output .marriage-line-margin3px{line-height:0;margin-bottom:-3px}.mw-parser-output .marriage-display-ws{display:inline;white-space:nowrap}, Rochelle Walensky (m. 1995)
Loren David Walensky is a professor of pediatrics and a professor of chemical biology at Harvard Medical School. He focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer, using synthetic chemistry, structural biology, and mouse modeling to develop new compounds to block protein interactions that cause cancer. He has developed stapled peptides that can neutralize selectively targeted proteins and treat human cancer.
People also ask
Who is Loren Walensky?
Who is Larry Walensky and what does he do?
Who is Dr Walensky?
What does the Walensky laboratory do?
Loren D. Walensky, MD, PhD . Physician ; Principal Investigator, Linde Program in Cancer Chemical Biology ; Professor of Pediatrics, Harvard Medical School ; Appointment Phone. 888-733-4662 (New Pediatric Patients) 617-632-3270 (Established Pediatric Patients) Fax. 617-582-8240
Loren Walensky is an attending physician and researcher at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. He specializes in pediatric hematology-oncology and develops novel peptide drugs for cancer treatment.
487. 2010. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. GL Verdine, LD Walensky. Clinical cancer research 13 (24), 7264-7270. , 2007. 474. 2007. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Professor of Pediatrics. The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer.
Related searches
